TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10382134

Group type: EXPERIMENTAL
Intervention: Questionnaires
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 22
Study: 9185440

Group type: EXPERIMENTAL
Intervention: Hepcon/HMS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 8447208

Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with neurolept analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with halothane
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with enflurane
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sufentanil (2 micrograms kg‐1 intravenous bolus) with isoflurane
Number of subjects: 56
Study: 3961308

Group type: EXPERIMENTAL
Intervention: Combination of social, medical and psychological interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30312754

Group type: EXPERIMENTAL
Intervention: Active tDCS (10 sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active tDCS (Phase II)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham tDCS (Phase II)
Number of subjects: 31
Study: 29167975

Group type: EXPERIMENTAL
Intervention: iPad™ application
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard verbal counseling (SVC)
Number of subjects: 60
Study: 27445550

Group type: EXPERIMENTAL
Intervention: IPPB therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IPPB and PEEP therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEEP therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPPB and PEEP therapy
Number of subjects: 0
Study: 24636695

Group type: EXPERIMENTAL
Intervention: Classic acupoint (Sanyinjiao, SP6)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Unrelated acupoint (Xuanzhong, GB39)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Non-acupoint
Number of subjects: 501
Study: 22510537

Group type: EXPERIMENTAL
Intervention: Behavioral physical therapy interventions
Number of subjects: 108

Group type: COMPARATOR
Intervention: Classification-based physical therapy
Number of subjects: 108
Study: 19092235

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg daily) + IPL therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: IPL therapy alone
Number of subjects: 70
Study: 17251674

Group type: EXPERIMENTAL
Intervention: Airway responsiveness to methacholine in CSA patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Airway responsiveness to methacholine in CP patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Airway responsiveness to methacholine in control subjects
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Geometric mean of log minimum dose (Dmin) in CSA patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Geometric mean of log minimum dose (Dmin) in CP patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Geometric mean of log minimum dose (Dmin) in control subjects
Number of subjects: 42
Study: 15570276

Group type: EXPERIMENTAL
Intervention: Compression plus superficial venous surgery
Number of subjects: 261

Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 261
Study: 12652992

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 7968646

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) TTS 0.05 mg/day for 6 months and 0.025 mg/day for the following six months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) TTS 0.10 mg/day for the first 6 months and 0.05 mg/day for the following 6 months
Number of subjects: 24
Study: 3112729

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (15 micrograms polysaccharide and 51 micrograms protein)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 28851238

Group type: EXPERIMENTAL
Intervention: Templestay program (Intensive Meditation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Relaxation (Control)
Number of subjects: 51
Study: 28061319

Group type: EXPERIMENTAL
Intervention: Adolescent and parent motivational intervention (Arm 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adolescent control and parent motivational intervention (Arm 2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Adolescent and parent control (Arm 3)
Number of subjects: 67
Study: 26319483

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (1.0 mg/kg)
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study: 23354394

Group type: EXPERIMENTAL
Intervention: Bitter orange extract (approximately 49mg p-synephrine) plus naringin and hesperidin, twice daily for 60 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bitter orange extract (approximately 49mg p-synephrine) alone, twice daily for 60 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo, twice daily for 60 days
Number of subjects: 25
Study: 20847735

Group type: EXPERIMENTAL
Intervention: Participation in obesity prevention trial
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Parents with college education
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Children with overweight vs. obese
Number of subjects: 804
Study: 18691700

Group type: EXPERIMENTAL
Intervention: Exposure session with safety gear (gloves and goggles)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exposure session without safety gear (control group)
Number of subjects: 62
Study: 16831092

Group type: EXPERIMENTAL
Intervention: 0.3 mg JS2 DNA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 mg JS2 DNA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: JS2 DNA (both doses)
Number of subjects: 30
Study: 12723015

Group type: EXPERIMENTAL
Intervention: Enalapril + Atenolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Enalapril + Prazosin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 28
Study: 10770766

Group type: COMPARATOR
Intervention: Quinine at 10 mg/kg three times a day for 7 days (Q)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Artemisinin at 20 mg/kg followed by quinine for 3 days (AQ3)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Artemisinin at 20 mg/kg followed by quinine for 5 days (AQ5)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 268

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 268
Study: 9340504

Group type: EXPERIMENTAL
Intervention: Double-bolus alteplase (50 mg over 1-3 minutes followed by 50 mg 30 minutes later, or 40 mg for patients <60 kg)
Number of subjects: 7169

Group type: COMPARATOR
Intervention: Accelerated infusion of alteplase (100 mg over 90 minutes)
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Double-bolus alteplase
Number of subjects: 7169

Group type: COMPARATOR
Intervention: Accelerated infusion of alteplase
Number of subjects: 7169
Study: 8438914

Group type: EXPERIMENTAL
Intervention: Loop diathermy excision
Number of subjects: 300

Group type: COMPARATOR
Intervention: Laser excisional conization
Number of subjects: 300
Study: 3110981

Group type: EXPERIMENTAL
Intervention: misoprostol 400 micrograms, twice daily for up to 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: ranitidine 150 mg, twice daily for up to 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 60

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 60
Study: 31517517

Group type: EXPERIMENTAL
Intervention: Societal cost information provided to patients
Number of subjects: 184

Group type: COMPARATOR
Intervention: No societal cost information provided to patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Patients declining surgery
Number of subjects: 184
Study: 29856928

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE; alternating 100% and 50% of peak oxygen uptake)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CME; 60% of peak oxygen uptake)
Number of subjects: 15
Study: 28837213

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20
Study: 26963198

Group type: EXPERIMENTAL
Intervention: Non-pedicled buccal fat pad graft (BFPG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 12
Study: 23123438

Group type: EXPERIMENTAL
Intervention: Electrical stimulation that induces visible muscle contraction (MOTOR group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with an intensity just above the sensory threshold (SENSORY group)
Number of subjects: 76
Study: 20397896

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) fluorescence-guided microsurgery
Number of subjects: 349

Group type: COMPARATOR
Intervention: Conventional white light (WL) microsurgery
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Combined endpoint of risks and neurological deficits in ALA group
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Incomplete resections in ALA group
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Scale (KPS) score
Number of subjects: 349
Study: 19213086

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg with closure device
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg with closure device
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg with smaller sheath size (<7 Fr)
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg with smaller sheath size (<7 Fr)
Number of subjects: 3528

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3528
Study: 17853749

Group type: EXPERIMENTAL
Intervention: EA at Qiuxu (GB 40)
Number of subjects: 275

Group type: COMPARATOR
Intervention: EA at Tianshu (ST 25)
Number of subjects: 275
Study: 15111165

Group type: EXPERIMENTAL
Intervention: PMEA-coated circuit (group P)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (group H)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Noncoated circuit (group N)
Number of subjects: 45
Study: 11266495

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (standard medical care only)
Number of subjects: 32
Study: 9153333

Group type: EXPERIMENTAL
Intervention: Scrotal system (Testoderm Testosterone Transdermal System) delivering approximately 4 mg testosterone over 24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonscrotal system (Androderm Testosterone Transdermal System) providing approximately 5 mg testosterone over 24 hours
Number of subjects: 60
Study: 8239592

Group type: EXPERIMENTAL
Intervention: SCE-2787
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 12
Study: 3687521

Group type: EXPERIMENTAL
Intervention: Nicotine-fading smoking program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fagerstrom Tolerance Questionnaire (FTQ)
Number of subjects: 0
Study: 28481837

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 129
Study: 26398327

Group type: EXPERIMENTAL
Intervention: Exercise self‐monitoring plus incentives ($2 per day for diary submissions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Home‐based exercise self‐monitoring program (control)
Number of subjects: 27
Study: 25631635

Group type: EXPERIMENTAL
Intervention: eHealth program (3 video conferencing interviews + 1 hospital visit for low-risk; 6 hospital visits + 6 video conferencing for high-risk)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care (4 hospital visits per year for low-risk; 6 hospital visits for high-risk)
Number of subjects: 250
Study: 24014884

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil continuous infusion (800 mg/m2/day, ci, d1-5, q4w)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Methotrexate and 5-fluorouracil therapy (methotrexate, 100 mg/m2, bolus infusion, followed 3 h later by 5-fluorouracil, 600 mg/m2, bolus infusion, with leucovorin rescue, q1w)
Number of subjects: 237
Study: 21911948

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% (Colgate Periogard)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride 0.05% (Johnson and Johnson's Reach)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18
Study: 18454257

Group type: EXPERIMENTAL
Intervention: Natural honey (70 g daily for 30 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sucrose (70 g daily for 30 days)
Number of subjects: 55
Study: 16911289

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT) (160 mg g1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 30
Study: 12821233

Group type: EXPERIMENTAL
Intervention: Intravenous acetylcysteine (NAC) 150 mg/kg in 500 ml N/saline over 30 min immediately before contrast followed by 50 mg/kg in 500 ml N/saline over 4 h (n = 41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous hydration (1 ml/kg/h N/saline for 12 h pre‐ and post‐contrast, n = 39)
Number of subjects: 80
Study: 10913474

Group type: EXPERIMENTAL
Intervention: Abciximab plus heparin (70 U/kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Heparin alone (70 U/kg)
Number of subjects: 46
Study: 8902660

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 1517792

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 16 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 120 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 147 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 14 mg/kg and Cyclophosphamide (CY) 174 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 20
Study: 6471030

Group type: EXPERIMENTAL
Intervention: Influenza Vaccine A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza Vaccine B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up study
Number of subjects: 0
Study: 28658080

Group type: EXPERIMENTAL
Intervention: HIGHW:R‐3×15:44s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOWW:R‐3×15:88s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOWW:R‐45×1:4s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOWW:R‐9×5:22s
Number of subjects: 20
Study: 29843654

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (50-min presentation by a skin cancer specialist nurse and young adult skin cancer survivor)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 639
Study: 26641555

Group type: EXPERIMENTAL
Intervention: Performance improvement interventions including physician education, case management, web-based decision support (CareManager(TM)), and performance feedback.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CareManager(TM) implementation and health system-wide COPD performance improvement efforts.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CareManager(TM) and performance improvement interventions.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Interventions for patients naïve to depression screening, pneumococcal vaccination, inhaled control medications, or smoking cessation.
Number of subjects: 242
Study: 25031533

Group type: EXPERIMENTAL
Intervention: AKL1
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23300553

Group type: EXPERIMENTAL
Intervention: Regulating anger via reappraisal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulating anger via distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angered participants
Number of subjects: 0
Study: 20716817

Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (3x10^9, 3x10^10, and 3x10^11 DNase resistant particles/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (high dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (low and mid-dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17929487

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of a local anesthetic
Number of subjects: 48

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 48
Study: 15546807

Group type: EXPERIMENTAL
Intervention: Lozenge containing lavender oil, extracts from hops, lemon balm and oat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo lozenge without active ingredients
Number of subjects: 16
Study: 11177061

Group type: EXPERIMENTAL
Intervention: Intervention group (5 hours of experiential instruction on injury prevention content and counseling skills)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (1-hour seminar about injury prevention and TIPP materials)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intervention group and Control group
Number of subjects: 196
Study: 9661080

Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg/day; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 7817022

Group type: EXPERIMENTAL
Intervention: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, immediate vitrectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, vitreous tap and treatment with or without intravenous antibiotics
Number of subjects: 34
Study: 3178249

Group type: EXPERIMENTAL
Intervention: 5% topical bufexamac
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31216961

Group type: EXPERIMENTAL
Intervention: Thrombus with distal location
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Higher clot burden score (CBS)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Shorter thrombus length
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Thrombus perviousness
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Distal thrombi
Number of subjects: 408
Study: 28622349

Group type: EXPERIMENTAL
Intervention: Running 5 km at maximal speed
Number of subjects: 17

Group type: COMPARATOR
Intervention: Day of rest (control)
Number of subjects: 17
Study: 26039968

Group type: EXPERIMENTAL
Intervention: AfH (AutoSet for her)
Number of subjects: 20

Group type: COMPARATOR
Intervention: AutoSet
Number of subjects: 20
Study: 23211042

Group type: EXPERIMENTAL
Intervention: Chronic periodontitis (CP) in ED group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Chronic periodontitis (CP) in non-ED group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Plaque index (PI), bleeding on probing (BoP), probing depth (PD), clinical attachment level (CAL) in ED group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Decayed, missing, filled teeth scores in ED group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of ED and CP severity
Number of subjects: 162
Study: 22120857

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Enalapril or Amlodipine without Atorvastatin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy Volunteers
Number of subjects: 74

Group type: COMPARATOR
Intervention: Hypertensive Patients
Number of subjects: 74
Study: 19168326

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Serratiopeptidase
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15254494

Group type: EXPERIMENTAL
Intervention: Topical autologous serum application (20% diluted with physiological saline, applied four times a day for up to 12 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical antibiotic and autologous serum
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (antibiotic alone)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical autologous serum application
Number of subjects: 42
Study: 12198602

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Coeliac disease
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: LADA
Number of subjects: 519

Group type: COMPARATOR
Intervention: MS
Number of subjects: 519

Group type: COMPARATOR
Intervention: ATD
Number of subjects: 519

Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 519
Study: 9787367

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Dorzolamide (2%) three times daily and timolol (0.5%) twice daily
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Number of subjects: 242
Study: 7616872

Group type: COMPARATOR
Intervention: Estradiol implants 50 mg alone (E)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg plus testosterone 50 mg (E&T)
Number of subjects: 34
Study: 2239120

Group type: EXPERIMENTAL
Intervention: Methohexital 80 mg/ml, 20 mg/kg rectally, 15 min before transportation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pentobarbital 28 mg/ml, 7 mg/kg rectally, 45 min before transportation
Number of subjects: 30
Study: 366263

Group type: EXPERIMENTAL
Intervention: Metoprolol 1% and 3% eye drops
Number of subjects: 0